Oragenics (OGEN) News Today $0.18 0.00 (-2.02%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.18 +0.00 (+1.71%) As of 04/17/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion TrialApril 9, 2025 | finance.yahoo.comOragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery SummitApril 7, 2025 | globenewswire.comOragenics provides Q1 shareholder update on strategic financial progressMarch 28, 2025 | markets.businessinsider.comOragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial ProgressMarch 27, 2025 | globenewswire.comOragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-KMarch 18, 2025 | globenewswire.comOragenics submits IB for Phase II clinical trial of ONP-002 in mTBIMarch 6, 2025 | markets.businessinsider.comOragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)March 6, 2025 | markets.businessinsider.comOragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)March 6, 2025 | globenewswire.comOragenics CMO to present at Emergencies in Medicine ConferenceFebruary 25, 2025 | markets.businessinsider.comOragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion TreatmentFebruary 25, 2025 | globenewswire.comOragenics announces partnership with BRAINBox SolutionsFebruary 11, 2025 | markets.businessinsider.comOragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and TreatmentFebruary 11, 2025 | globenewswire.comOragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025February 5, 2025 | globenewswire.comOragenics appoints Huffman as interim CEO, provides shareholder updateJanuary 23, 2025 | markets.businessinsider.comOragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEOJanuary 21, 2025 | globenewswire.comOragenics appoints interim CEO, ups CFO salaryJanuary 17, 2025 | msn.comOragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation PreferenceDecember 16, 2024 | globenewswire.comOragenics announces termination of president's employment agreementDecember 2, 2024 | investing.comOragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas SummitOctober 18, 2024 | globenewswire.comOragenics inks sales agreement for at-the-market stock offeringOctober 17, 2024 | investing.comBioMedNewsBreaks — Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion TreatmentOctober 9, 2024 | msn.comOragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial PreparationOctober 9, 2024 | globenewswire.comInvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Advances Concussion Treatment with Promising Study for Nasal Spray Drug ONP-002October 8, 2024 | msn.comEXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug CandidateOctober 8, 2024 | benzinga.comOragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002October 8, 2024 | globenewswire.comCore One Labs Inc. (LD6.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comOragenics, Inc. Announces Closing of Public OfferingSeptember 5, 2024 | globenewswire.comBioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Enters into Public Offering Agreement Estimated to Total $4.45MSeptember 4, 2024 | msn.comWhy Oragenics (OGEN) Stock Is Getting HammeredSeptember 4, 2024 | benzinga.comOragenics, Inc. Announces Pricing of Public OfferingSeptember 4, 2024 | globenewswire.comOragenics (AMEX:OGEN) Stock Quotes, Forecast and News SummaryAugust 25, 2024 | benzinga.comInvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Completes Manufacture, Filling of Intranasal Device for Use in Upcoming Clinical TrialAugust 21, 2024 | msn.comEXCLUSIVE: Oragenics Completes Spray Dry Drug Manufacturing, Intranasal Device Filling For Anticipated Mid-Stage Study For Patients With Brain InjuryAugust 21, 2024 | msn.comOragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed PatientsAugust 21, 2024 | globenewswire.comBioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat ConcussionAugust 19, 2024 | msn.comOragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing StandardsAugust 16, 2024 | globenewswire.comOragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature RangeAugust 14, 2024 | globenewswire.comOragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity StudyAugust 12, 2024 | globenewswire.comEXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase II Trials UnderwayAugust 8, 2024 | msn.comOragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity TestingAugust 8, 2024 | globenewswire.comOGEN Stock Earnings: Oragenics Reported Results for Q4 2023June 28, 2024 | investorplace.comOragenics Develops Automated Intranasal Device for Treating Concussed PatientsJune 27, 2024 | globenewswire.comOragenics, Inc. Announces Closing of Public OfferingJune 26, 2024 | globenewswire.comOragenics, Inc. Announces Pricing of Public OfferingJune 25, 2024 | globenewswire.comOragenics, Inc. Announces Proposed Public OfferingJune 24, 2024 | globenewswire.comOragenics Appoints William “Frank” Peacock MD as Chief Clinical OfficerMay 22, 2024 | globenewswire.comOragenics, Inc. to Host Webinar Panel on Neurotrauma MedicineMay 17, 2024 | globenewswire.comOragenics climbs 9% amid Phase 2 study, business updatesMay 16, 2024 | msn.comOragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion TrialMay 16, 2024 | finance.yahoo.comOGEN Stock Earnings: Oragenics Reported Results for Q1 2024May 16, 2024 | investorplace.com Get Oragenics News Delivered to You Automatically Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address OGEN Media Mentions By Week OGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OGEN News Sentiment▼0.000.57▲Average Medical News Sentiment OGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OGEN Articles This Week▼01▲OGEN Articles Average Week Get Oragenics News Delivered to You Automatically Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BriaCell Therapeutics News Today Eagle Pharmaceuticals News Today BioVie News Today MetaVia News Today Cingulate News Today MIRA Pharmaceuticals News Today GeoVax Labs News Today NeuroSense Therapeutics News Today GlycoMimetics News Today ImmunoPrecise Antibodies News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:OGEN) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OGEN Stock Free OGEN Stock Alerts